Incyte (NASDAQ: INCY) EVP reports sale and RSU tax withholding

Rhea-AI Filing Summary

Incyte executive Issa Mohamed Khairie reported two stock transactions. On 01/06/2026, 8,264 shares of common stock were automatically withheld by the issuer at a price of $106.66 to cover tax obligations tied to previously granted restricted stock units. On 01/07/2026, Khairie sold 10,856 shares of Incyte common stock at a price of $109.07 per share in an open market transaction. After these transactions, Khairie directly beneficially owned 66,132 shares of common stock, which includes shares issuable from previously reported RSUs that have not yet vested.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Issa Mohamed Khairie

(Last) (First) (Middle)

1801 AUGUSTINE CUT-OFF

(Street)

WILMINGTON DE 19803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INCYTE CORP [ INCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Head of US Oncology

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		F		8,264(1)	D	$106.66	76,988	D
Common Stock	01/07/2026		S		10,856	D	$109.07	66,132(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

2. This includes an aggregate of 66,132 shares of common stock issuable pursuant to previously reported RSUs that have not vested.

Remarks:

	/s/ Elizabeth Feeney, Attorney-In-Fact	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did INCYTE CORP (INCY) report for Issa Mohamed Khairie?

The filing reports that EVP and Head of US Oncology Issa Mohamed Khairie had 8,264 shares withheld for taxes on 01/06/2026 and sold 10,856 shares of Incyte common stock on 01/07/2026.

How many INCYTE CORP shares did the EVP sell, and at what price?

On 01/07/2026, Issa Mohamed Khairie sold 10,856 shares of INCYTE CORP common stock at a price of $109.07 per share.

What was the purpose of the 8,264 INCYTE CORP shares reported with code "F"?

The 8,264 shares reported with transaction code "F" on 01/06/2026 represent shares withheld automatically by Incyte to satisfy tax withholding obligations upon settlement of previously granted restricted stock units.

How many INCYTE CORP shares does Issa Mohamed Khairie beneficially own after these transactions?

Following the reported transactions, Issa Mohamed Khairie beneficially owned 66,132 shares of INCYTE CORP common stock, including shares issuable under previously reported RSUs that have not vested.

Does the Form 4 indicate whether the reported INCYTE CORP transactions are held directly or indirectly?

The Form 4 indicates that the reported holdings and transactions are direct, as shown by the ownership form "D" in the tables.

What is Issa Mohamed Khairie’s role at INCYTE CORP according to the Form 4?

According to the Form 4, Issa Mohamed Khairie is an officer of INCYTE CORP with the title EVP, Head of US Oncology.